Olatunji A. Godo

Array ( [id] => 17830013 [patent_doc_number] => 20220267317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 [patent_app_type] => utility [patent_app_number] => 17/519922 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18815887 [patent_doc_number] => 20230390226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => INTRANASAL ADMINISTRATION OF SURAMIN FOR TREATING NERVOUS SYSTEM DISORDERS [patent_app_type] => utility [patent_app_number] => 18/033167 [patent_app_country] => US [patent_app_date] => 2021-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806839 [patent_doc_number] => 20230381172 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 18/249134 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938097 [patent_doc_number] => 20240033236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF [patent_app_type] => utility [patent_app_number] => 18/030139 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368186 [patent_doc_number] => 20220023238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => Process of Manufacturing a Stable, Ready to Use Infusion Bag for an Oxidation Sensitive Formulation [patent_app_type] => utility [patent_app_number] => 17/496276 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17836345 [patent_doc_number] => 20220273650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => TREATMENT OF CANCER WITH TOR KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/496433 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17836345 [patent_doc_number] => 20220273650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => TREATMENT OF CANCER WITH TOR KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/496433 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692480 [patent_doc_number] => 20230322743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES [patent_app_type] => utility [patent_app_number] => 18/024517 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692480 [patent_doc_number] => 20230322743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES [patent_app_type] => utility [patent_app_number] => 18/024517 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290871 [patent_doc_number] => 20210386710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN [patent_app_type] => utility [patent_app_number] => 17/461325 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 333 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290912 [patent_doc_number] => 20210386751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => TREATMENT WITH P2X3 MODULATORS [patent_app_type] => utility [patent_app_number] => 17/461988 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065744 [patent_doc_number] => 20240100170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/043269 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752380 [patent_doc_number] => 20230355612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => PHARMACEUTICALLY ACCEPTABLE SALT OF CARIPRAZINE AND CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/043000 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752380 [patent_doc_number] => 20230355612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => PHARMACEUTICALLY ACCEPTABLE SALT OF CARIPRAZINE AND CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/043000 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18690926 [patent_doc_number] => 20230321094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => COMBINATION THERAPIES WITH OLIG2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/042497 [patent_app_country] => US [patent_app_date] => 2021-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18610758 [patent_doc_number] => 20230277488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => DRUG COMBINATION AND ITS USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/019454 [patent_app_country] => US [patent_app_date] => 2021-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372404 [patent_doc_number] => 12479826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Pyridazinyl amino derivatives as ALK5 inhibitors [patent_app_type] => utility [patent_app_number] => 18/014764 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58732 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 382 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372404 [patent_doc_number] => 12479826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Pyridazinyl amino derivatives as ALK5 inhibitors [patent_app_type] => utility [patent_app_number] => 18/014764 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58732 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 382 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18550672 [patent_doc_number] => 20230248672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES [patent_app_type] => utility [patent_app_number] => 18/015592 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656087 [patent_doc_number] => 20230301958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => SATRAPLATIN FOR USE IN THE TREATMENT OF LYMPHOID NEOPLASMS [patent_app_type] => utility [patent_app_number] => 18/015002 [patent_app_country] => US [patent_app_date] => 2021-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015002 [rel_patent_id] =>[rel_patent_doc_number] =>)